α2 −プラスミンインヒビタ−の測定方法及び測定試 薬

Method and reagent for determining alpha2-plasmin inhibitor

Abstract

(57)【要約】 【目的】 再溶解したり、希釈したりせず、すなわち、 試薬調製に時間と手間のかからない、かつ、長時間、測 定試薬を保存しておいても、正確にα 2 −PIを測定で きる方法を提供する。 【構成】 α 2 −プラスミンインヒビタ−を含む血漿 に、スクロースを含むプラスミン試薬を添加し、次ぎ に、得られる混合液の残存プラスミンとプラスミン合成 基質試薬を反応させることにより、そのα 2 −プラスミ ンインヒビタ−を測定する。
PROBLEM TO BE SOLVED: To provide a convenient and accurate method for determining an α2-plasmin inhibitor for clinical examinations, etc., by mixing and reacting a plasmin-containing sample with a plasmin reagent which contains an excess of a specific non-reducing sugar, and measuring activity of the remaining plasmin. SOLUTION: The objective convenient and accurate method for determining an α2-plasmin inhibitor to be used for e.g. clinical examinations is to mix an α2-plasmin containing sample (e.g. plasma specimen) with a plasmin reagent which contains an excess of specific non-reducing sugar to make the plasmin react with the α2-plasmin inhibitor, and then determine the α2-plasmin inhibitor remaining in the sample. The plasmin reagent to be used is a liquid one that contains 1-60% of a 4-24C non-reducing sugar such as sorbitol, trehalose or sucrose, 0.005-3.0mol of a salt and 0.001-100 units/ml of plasmin.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (0)

    Publication numberPublication dateAssigneeTitle

NO-Patent Citations (0)

    Title

Cited By (13)

    Publication numberPublication dateAssigneeTitle
    EP-1232251-A1August 21, 2002Bayer CorporationVerfahren zur thrombolyse durch lokale behandlung mit reversibel inaktiviertem, angesäuertem plasmin
    EP-1232251-A4September 01, 2004Bayer Healthcare LlcProcede de thrombolyse par administration locale de plasmine acidifiee inactivee de maniere reversible
    EP-1232251-B2May 17, 2017Grifols Therapeutics Inc.Procede de thrombolyse par administration locale de plasmine acidifiee inactivee de maniere reversible
    EP-1232252-A1August 21, 2002Bayer CorporationPlasmine acidifiee inactivee de maniere reversible
    EP-1232252-A4October 20, 2004Bayer Healthcare LlcReversibly inactivated acidified plasmin
    EP-1232254-A1August 21, 2002Bayer CorporationProcess for the production of a reversibly inactive acidified plasmin composition
    EP-1232254-A4February 02, 2005Bayer Healthcare LlcVERFAHREN ZUR HERSTELLUNG EINER REVERSIBEL INAKTIVEN, ANGESäUERTEN PLASMINZUSAMMENSETZUNG
    US-6964764-B2November 15, 2005Talecris Biotherapeutics, Inc.Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
    US-6969515-B2November 29, 2005Talecris Biotherapeutics, Inc.Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
    US-7544500-B2June 09, 2009Talecris Biotherapeutics, Inc.Process for the production of a reversibly inactive acidified plasmin composition
    US-7871608-B2January 18, 2011Talecris Biotherapeutics, Inc.Reversibly inactivated acidified plasmin
    US-8268782-B2September 18, 2012Grifols Therapeutics Inc.Composition and method for preparing plasminogen
    US-9879246-B2January 30, 2018Grifols Therapeutics Inc.Reversibly inactivated acidified plasmin composition